188 related articles for article (PubMed ID: 29917164)
21. Downregulation of long noncoding RNA NONHSAT037832 in papillary thyroid carcinoma and its clinical significance.
Lan X; Sun W; Zhang P; He L; Dong W; Wang Z; Liu S; Zhang H
Tumour Biol; 2016 May; 37(5):6117-23. PubMed ID: 26611646
[TBL] [Abstract][Full Text] [Related]
22. Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma.
Chou CK; Yang KD; Chou FF; Huang CC; Lan YW; Lee YF; Kang HY; Liu RT
J Clin Endocrinol Metab; 2013 Feb; 98(2):E196-205. PubMed ID: 23264400
[TBL] [Abstract][Full Text] [Related]
23. Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers.
Uddin S; Siraj AK; Al-Rasheed M; Ahmed M; Bu R; Myers JN; Al-Nuaim A; Al-Sobhi S; Al-Dayel F; Bavi P; Hussain AR; Al-Kuraya KS
J Clin Endocrinol Metab; 2008 Oct; 93(10):4088-97. PubMed ID: 18682509
[TBL] [Abstract][Full Text] [Related]
24. Src inhibitors in suppression of papillary thyroid carcinoma growth.
Henderson YC; Toro-Serra R; Chen Y; Ryu J; Frederick MJ; Zhou G; Gallick GE; Lai SY; Clayman GL
Head Neck; 2014 Mar; 36(3):375-84. PubMed ID: 23729178
[TBL] [Abstract][Full Text] [Related]
25. ZNRF3 is downregulated in papillary thyroid carcinoma and suppresses the proliferation and invasion of papillary thyroid cancer cells.
Qiu W; Yang Z; Fan Y; Zheng Q
Tumour Biol; 2016 Sep; 37(9):12665-12672. PubMed ID: 27448298
[TBL] [Abstract][Full Text] [Related]
26. A constitutive active MAPK/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTC.
Occhi G; Barollo S; Regazzo D; Bertazza L; Galuppini F; Guzzardo V; Jaffrain-Rea ML; Vianello F; Ciato D; Ceccato F; Watutantrige-Fernando S; Bisognin A; Bortoluzzi S; Pennelli G; Boscaro M; Scaroni C; Mian C
Oncotarget; 2015 Oct; 6(31):32104-14. PubMed ID: 26392334
[TBL] [Abstract][Full Text] [Related]
27. MAPK and SHH pathways modulate type 3 deiodinase expression in papillary thyroid carcinoma.
Romitti M; Wajner SM; Ceolin L; Ferreira CV; Ribeiro RV; Rohenkohl HC; Weber Sde S; Lopez PL; Fuziwara CS; Kimura ET; Maia AL
Endocr Relat Cancer; 2016 Mar; 23(3):135-46. PubMed ID: 26825960
[TBL] [Abstract][Full Text] [Related]
28. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK
Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403
[TBL] [Abstract][Full Text] [Related]
29. FoxM1 and its association with matrix metalloproteinases (MMP) signaling pathway in papillary thyroid carcinoma.
Ahmed M; Uddin S; Hussain AR; Alyan A; Jehan Z; Al-Dayel F; Al-Nuaim A; Al-Sobhi S; Amin T; Bavi P; Al-Kuraya KS
J Clin Endocrinol Metab; 2012 Jan; 97(1):E1-E13. PubMed ID: 22049175
[TBL] [Abstract][Full Text] [Related]
30. Cellular apoptosis susceptibility (CAS) is overexpressed in thyroid carcinoma and maintains tumor cell growth: A potential link to the BRAFV600E mutation.
Holzer K; Drucker E; Oliver S; Winkler J; Eiteneuer E; Herpel E; Breuhahn K; Singer S
Int J Oncol; 2016 Apr; 48(4):1679-87. PubMed ID: 26892809
[TBL] [Abstract][Full Text] [Related]
31. [Expression of BRAF and its extracellular signal-regulated kinase 1/2 signal pathway in papillary thyroid cancer].
Yi W; Zhong D; Zou Q
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Sep; 37(9):889-94. PubMed ID: 23000762
[TBL] [Abstract][Full Text] [Related]
32. MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway.
Ma Y; Qin H; Cui Y
Biochem Biophys Res Commun; 2013 Nov; 441(4):958-63. PubMed ID: 24220341
[TBL] [Abstract][Full Text] [Related]
33. LDOC1 inhibits proliferation and promotes apoptosis by repressing NF-κB activation in papillary thyroid carcinoma.
Zhao S; Wang Q; Li Z; Ma X; Wu L; Ji H; Qin G
J Exp Clin Cancer Res; 2015 Dec; 34():146. PubMed ID: 26637328
[TBL] [Abstract][Full Text] [Related]
34. Upregulation of long noncoding RNA LOC100507661 promotes tumor aggressiveness in thyroid cancer.
Kim D; Lee WK; Jeong S; Seol MY; Kim H; Kim KS; Lee EJ; Lee J; Jo YS
Mol Cell Endocrinol; 2016 Aug; 431():36-45. PubMed ID: 27151833
[TBL] [Abstract][Full Text] [Related]
35. Upregulated miR-155 in papillary thyroid carcinoma promotes tumor growth by targeting APC and activating Wnt/β-catenin signaling.
Zhang X; Li M; Zuo K; Li D; Ye M; Ding L; Cai H; Fu D; Fan Y; Lv Z
J Clin Endocrinol Metab; 2013 Aug; 98(8):E1305-13. PubMed ID: 23796566
[TBL] [Abstract][Full Text] [Related]
36. Receptor for activated protein C kinase 1 (RACK1) is overexpressed in papillary thyroid carcinoma.
Myklebust LM; Akslen LA; Varhaug JE; Lillehaug JR
Thyroid; 2011 Nov; 21(11):1217-25. PubMed ID: 22007921
[TBL] [Abstract][Full Text] [Related]
37. MiRNA-146b-5p upregulates migration and invasion of different Papillary Thyroid Carcinoma cells.
Lima CR; Geraldo MV; Fuziwara CS; Kimura ET; Santos MF
BMC Cancer; 2016 Feb; 16():108. PubMed ID: 26883911
[TBL] [Abstract][Full Text] [Related]
38. MiR-221 Exacerbate Cell Proliferation and Invasion by Targeting TIMP3 in Papillary Thyroid Carcinoma.
Diao Y; Fu H; Wang Q
Am J Ther; 2017 May; 24(3):e317-e328. PubMed ID: 27077469
[TBL] [Abstract][Full Text] [Related]
39. Over-expression of long noncoding RNA BANCR inhibits malignant phenotypes of human bladder cancer.
He A; Liu Y; Chen Z; Li J; Chen M; Liu L; Liao X; Lv Z; Zhan Y; Zhuang C; Lin J; Huang W; Mei H
J Exp Clin Cancer Res; 2016 Aug; 35(1):125. PubMed ID: 27514530
[TBL] [Abstract][Full Text] [Related]
40. Long non-coding RNA BANCR regulates growth and metastasis and is associated with poor prognosis in retinoblastoma.
Su S; Gao J; Wang T; Wang J; Li H; Wang Z
Tumour Biol; 2015 Sep; 36(9):7205-11. PubMed ID: 25894373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
